Real-time enrollment status for this triple negative breast cancer clinical trial
Current Status
Recruiting
Checked: August 28, 2026 at 1:20 PM UTC
| NCT Number | NCT06022029 |
| Recruiting Status | Recruiting |
| Condition | Triple Negative Breast Cancer |
| Phase | PHASE1 |
| Target Enrollment | 168 participants |
| Active Locations | 9 sites in the US |
| Sponsor | OncoNano Medicine, Inc. |
| Last Updated on CT.gov | December 24, 2025 (Dec 24, 2025) |
As of August 28, 2026: Clinical trial NCT06022029 is currently recruiting participants. This phase1 study for triple negative breast cancer is actively seeking new participants at 9 locations across the United States. The study is sponsored by OncoNano Medicine, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06022029 is actively recruiting participants as of August 28, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 9 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06022029 was last updated Dec 24, 2025 (December 24, 2025). HelloStudys verifies this status automatically.